Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 May 2023 | Story Leonie Bolleurs | Photo Supplied
Prof André Roodt
Prof Andreas Roodt was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns. He will receive the prize, sponsored by Sanlam, at a function scheduled for September this year.

Prof Andreas Roodt, former Head of the Department of Chemistry at the University of the Free State (UFS) and retired Distinguished Professor in the same department, was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns.

The prize, a major recognition of his life's work, was presented to him for his contribution to the exploration and sustained development of natural science and technology and the successful application thereof in broader society.

Impacting society

About receiving the prize, he says it was a big surprise, but he is very proud to be honoured with this special award, “being an Afrikaans kid from a ‘platteland’ school outside Bloemfontein.”

Prof Roodt’s research focuses on understanding the reaction mechanisms of mainly inorganic coordination chemical systems that are critical to different industrial, medical, environmental, and metal beneficiation processes.

His research, for instance, contributes to important compounds and processes relevant to nuclear medicine and potential cancer therapy. Not so long ago, he registered a patent on this in Europe, Japan, and the USA that could help to diagnose and potentially treat cancer-related tumours in the future.

In addition, he continues to work on several projects aimed at developing cleaner industrial processes in the South African petrochemical industry. He is also focusing on more efficient ways of accessing the country’s mineral resources.

Career highlights

Throughout his academic career, Prof Roodt has achieved many significant milestones. He was extensively involved in crystallography for more than 30 years. One of his career highlights was being elected as the President of the European Crystallographic Association from 2012 to 2015, an organisation with more than 35 member countries.

In this field, he established an X-ray crystallographic facility in the UFS Department of Chemistry, which was officially named the ‘Roodt XRD Lab’ at the end of 2021.

He also sees his journey with the diverse group of 41 PhD and 54 MSc students (Afrikaans, English, Sesotho, Setswana, and isiXhosa) as another notable achievement in his career.

Other outstanding moments in Prof Roodt's career were his collaborations with research leaders from countries such as the USA, UK, Switzerland, Italy, Sweden, France, Croatia, India, Japan, Russia, the Netherlands, Germany, and Tunisia. These collaborations have allowed him to be recognised by peers worldwide and have demonstrated that Africa and South Africa can produce high-quality and relevant research that can compete on an international level.

The future

Despite his appointment as a Distinguished Professor and his commitment to finishing uncompleted work and assisting younger colleagues both in South Africa and abroad, Prof Roodt retired more than a year ago. He is now enjoying his retirement with his wife, children, and grandchildren, while also devoting time to his passion for collecting aloe plants and generating new hybrids.

News Archive

UFS researcher explores the future cost of cancer
2017-01-10

 Description: 001 Dr Alicia Sherriff Tags: 001 Dr Alicia Sherriff

Dr Alicia Sherriff, Head the Department of Oncology
at the UFS Faculty of Health Sciences, co-authored
an article in the South African Medical Journal.

Photo: Charl Devenish

Cancer is on an exponential rise globally, and the cost of treatment is a growing international problem. South Africa alone is expected to see a 78% increase in cancer cases. Dr Alicia Sheriff, Head of the Department of Oncology, collaborated on and co-authored a research paper for the South African Medical Journal on the future of oncology treatment in the country, along with doctors from various universities across South Africa. The article, titled "The future cost of cancer: interdisciplinary cost management strategy", looks at the prognosis of cancer management in the country.

Cancer is on the rise

There is a visible growth of the cancer disease in the developing world. Rapidly changing lifestyles, uncontrolled urbanisation, pollution, and population ageing are some dynamics that provide a lethal cocktail of infectious and lifestyle risk factors that leave people at a higher risk of developing cancer.

The simultaneous increase in cancer incidence has increased the cost of treatment exponentially. The cost of cancer treatment is multitiered, making the provision of care for cancer patients a high-risk business. A combination of treatment delays, limited resources, differently skilled personnel, high patient volumes and advanced disease stage on presentation all place a bigger burden on the delivery of optimal cancer care outcomes.

Adoption of new strategies

According to the doctors, innovative thinking to embrace technology, combined with a preventive approach, as well as lowering the cost of treatment drugs should be prioritised. So should the commercialisation of new technologies that will diagnose and treat cancer in its early stages. They also encourage interdisciplinary research funding in South Africa as a way to better understand the demographic and molecular dynamics of cancer in the country, along with retaining more oncologists in the public health sector.

Efficient solutions to curb cancer mortality

The doctors assert there is a need to continue to look for more efficient measures to best treat the disease, and hopefully bring about a change in mortality levels in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept